What Is Tirzepatide?
Tirzepatide is a prescription medication that activates two incretin hormone receptors:
1.Glucose-dependent insulinotropic polypeptide (GIP) receptor.
2.Glucagon-like peptide-1 (GLP-1) receptor.
These hormonal pathways participate in regulating blood glucose, appetite, and food intake.
Tirzepatide works through both receptors and may help eligible individuals manage body weight when used alongside an appropriate nutrition and physical activity plan.
Its effects include:
1.Supporting appetite regulation and reduced food intake.
2.Influencing glucose-dependent insulin secretion.
3.Affecting gastric emptying.
4.Supporting improvements in body weight in eligible patients when used for an approved indication.
Tirzepatide is not a standalone solution for obesity. Its use requires appropriate medical assessment, consideration of individual risk factors, and ongoing monitoring.
Mounjaro vs Zepbound: What Is the Difference?
Mounjaro and Zepbound contain the same active ingredient: tirzepatide. However, they have different FDA-approved indications in the United States.
Mounjaro (Tirzepatide)
Mounjaro is FDA-approved as an adjunct to diet and exercise to improve blood glucose control in adults and children aged 10 years and older with type 2 diabetes.
Its US labeling also includes reduction of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.
Mounjaro should not be represented as the FDA-approved chronic weight-management brand.
Zepbound (Tirzepatide)
Zepbound is FDA-approved, in combination with a reduced-calorie diet and increased physical activity, for:
1.Reducing excess body weight and maintaining long-term weight reduction in adults with obesity.
2.Adults with overweight who have at least one weight-related medical condition.
3.Treating moderate-to-severe obstructive sleep apnea in adults with obesity.
The appropriate medication and indication depend on the individual's medical circumstances and prescribing requirements.
Important: Mounjaro and Zepbound both contain tirzepatide. They should not be used together or combined with another GLP-1 receptor agonist.
How Does Tirzepatide Work?
Tirzepatide acts on GIP and GLP-1 receptors, which are involved in several metabolic processes.
1. Appetite and Food Intake: Tirzepatide influences appetite-regulating pathways and may reduce hunger and food intake in some individuals.
2. Glucose Regulation: It enhances glucose-dependent insulin secretion and helps regulate blood glucose levels.
3. Gastric Emptying: Tirzepatide delays gastric emptying, particularly during the initial stages of treatment. This can influence feelings of fullness and post-meal glucose responses.
4. Body Weight Management: Through its effects on appetite, food intake, and metabolic regulation, tirzepatide can support weight reduction in eligible adults when used according to its approved indication alongside dietary and physical activity interventions.
Individual responses vary, and treatment outcomes cannot be guaranteed.
Who May Be Considered for Tirzepatide Treatment?
Tirzepatide may be considered for adults who meet the relevant prescribing criteria and have undergone an appropriate medical assessment.
For chronic weight management with Zepbound, the FDA-approved adult eligibility criteria include:
1. A BMI of 30 kg/m² or greater (obesity).
2. A BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition.
Relevant weight-related conditions may include high blood pressure, abnormal cholesterol, type 2 diabetes, and obstructive sleep apnea.
A BMI calculation alone does not determine treatment suitability.
The healthcare provider must also consider medical history, existing medications, previous weight-management approaches, potential contraindications, and individual treatment goals.
Not everyone seeking weight loss will be an appropriate candidate for tirzepatide.
Your Online Tirzepatide Consultation with Amaya
Amaya follows an individualized clinical assessment process rather than recommending medication based on weight or BMI alone.
Our online consultation process is designed to understand your health history, identify relevant medical considerations and determine whether further evaluation is appropriate.
Step 1: Initial Consultation
Begin by contacting Amaya to arrange an appointment.
Consultations are conducted through video or telephone, depending on your preference and clinical requirements.
During the initial interview, the healthcare provider discusses:
1. Your current weight and weight-management goals.
2. Medical history and existing health conditions.
3. Previous weight-loss attempts and treatments.
4. Current prescription medications and supplements.
5. Relevant family history.
6. Lifestyle, nutrition, and activity patterns.
Step 2: Laboratory Testing, When Indicated
Following the initial interview and clinical assessment, laboratory investigations may be recommended when clinically appropriate.
Amaya coordinates the required tests through established diagnostic laboratory networks near your location in Texas.
You do not need to independently arrange the laboratory process before speaking with us.
The specific investigations depend on your medical history and clinical needs. They may include assessments of blood glucose, HbA1c, kidney and liver function, lipid profile and other relevant parameters.
Step 3: Review of Results and Clinical Assessment
Laboratory results are reviewed by the healthcare provider alongside your medical history, current medications, and clinical findings.
The purpose is to identify relevant health considerations and assess whether a prescription-based treatment approach is appropriate.
Having normal laboratory results does not automatically qualify someone for tirzepatide treatment.
Step 4: Individualized Treatment Plan
If clinically appropriate, the healthcare provider discusses suitable treatment options.
This may include consideration of an approved tirzepatide product, relevant alternatives, nutrition, physical activity, and other aspects of medical weight management.
A prescription is issued only when the healthcare provider determines that treatment is medically appropriate.
A consultation does not guarantee a prescription.
Step 5: Follow-Up and Monitoring
Medical weight management requires continued evaluation.
Follow-up consultations help assess treatment response, tolerability, changes in weight, and relevant metabolic parameters.
Treatment decisions, including dose adjustments or discontinuation, are made by the prescribing healthcare provider.
Possible Side Effects
Common gastrointestinal side effects include:
1. Nausea.
2. Diarrhea.
3. Vomiting.
4. Constipation.
5. Abdominal discomfort or pain.
6. Indigestion.
7. Reduced appetite.
Other important potential risks include:
1. Acute pancreatitis.
2. Gallbladder disease.
3. Dehydration and associated kidney problems.
4. Serious gastrointestinal reactions.
5. Hypoglycemia, particularly when used with insulin or insulin-releasing medications.
6. Serious allergic reactions.
Tirzepatide is not recommended for patients with severe gastroparesis.
Pregnancy and Other Precautions
Weight-loss treatment with Zepbound is not appropriate during pregnancy. Patients who become pregnant should contact their healthcare provider promptly.
Tirzepatide can affect the absorption of oral medications by delaying gastric emptying. Women using oral contraceptives should discuss the additional contraceptive precautions recommended in the prescribing information, particularly after starting treatment or increasing the dose.
Patients should also inform their healthcare providers about tirzepatide use before planned surgery or procedures involving general anesthesia or deep sedation.
The healthcare provider should review the complete prescribing information before initiating treatment.
Frequently Asked Questions About Tirzepatide, Mounjaro and Zepbound
1. Is Tirzepatide the same as Mounjaro?
Tirzepatide is the active pharmaceutical ingredient. Mounjaro is one of its brand names in the United States. Zepbound is another brand containing the same active ingredient, with a different FDA-approved indication.
2. Is Mounjaro FDA-approved for weight loss?
Mounjaro is FDA-approved for improving blood glucose control in people with type 2 diabetes, with an additional cardiovascular risk-reduction indication for certain adults with type 2 diabetes. It is not the FDA-approved chronic weight-management brand. Zepbound is the tirzepatide brand approved for chronic weight management in eligible adults.
3. Can someone without diabetes use tirzepatide for weight management?
Eligible adults without diabetes may be considered for Zepbound under its FDA-approved chronic weight-management indication. Eligibility requires an appropriate clinical assessment and the applicable BMI and comorbidity criteria.
4. How does tirzepatide help with weight loss?
Tirzepatide activates GIP and GLP-1 receptors involved in appetite regulation, food intake, and metabolic processes. It can help eligible individuals reduce body weight when combined with reduced-calorie nutrition and increased physical activity.
5. Is tirzepatide taken daily or weekly?
Approved Mounjaro and Zepbound injections are administered once weekly. The prescribed dose and any dose adjustments must be determined by the healthcare provider. Patients should follow the instructions for their specific prescribed product.
6. Do I need laboratory tests before starting tirzepatide?
Laboratory investigations may be recommended depending on your medical history and clinical assessment. If testing is indicated, Amaya coordinates the required tests through established diagnostic laboratory networks near your location in Texas. Results are reviewed before prescription decisions are made.
7. Can I have an online Mounjaro or Zepbound consultation in Texas?
Yes. Amaya offers appointment-based video and telephone consultations to eligible patients physically located in Texas. The healthcare provider will review your medical history and determine whether further evaluation or treatment is appropriate.
8. Does an online consultation guarantee a tirzepatide prescription?
No. A prescription is not guaranteed. Treatment is considered only after reviewing medical history, relevant laboratory results, eligibility criteria, contraindications and individual clinical circumstances.
9. Can I use Mounjaro and Zepbound together?
No. Both contain tirzepatide and should not be used together. Combining tirzepatide with another GLP-1 receptor agonist is also not recommended.
10. How do I arrange an online consultation with Amaya?
Amaya at 713-772-7887, send a WhatsApp inquiry, or submit a message through the website contact form. The team will assist with arranging an appointment.